Navigation Links
Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
Date:3/27/2013

PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase 2, randomized, double-blind, placebo-controlled, dose-escalating clinical study of SGX942 in patients being treated for head and neck cancer.  The trial is expected to be initiated in the second half of 2013.

"Oral mucositis is a significant unmet medical need which ultimately impacts the tolerability of radiation and chemotherapy and therefore the survivability of cancer," stated Stephen T Sonis, DMD, DMSc, Clinical Professor of Oral Medicine at Harvard School of Dental Medicine and a Member of the Soligenix Oral Mucositis Medical Advisory Board.  "The lack of an effective treatment has frustrated healthcare providers and caused misery for innumerable patients. As an innate defense regulator (IDR), SGX942 directly targets a fundamental biological mechanism which leads to mucosal injury caused by radiation and chemotherapy."

"We are pleased that the FDA has cleared Soligenix's first IND for the recently acquired IDR technology," stated Christopher J. Schaber , PhD, President and Chief Executive Officer of Soligenix. "The initiation of the oral mucositis clinical program marks an important next step in the development of SGX942.  We look forward to working with our esteemed Medical Advisory Board and clinical investigators to initiate this clinical study."

About SGX942

SGX942 is an IDR, a new class of short, synthetic peptides that has a novel mechanism of action in that it has simu
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
4. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
5. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
6. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
9. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
10. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
11. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Inovio ... today it has initiated a phase I clinical ... will evaluate the safety, tolerability, and immunogenicity of ... (HPV-6), which causes most aerodigestive cancers. ... throat, vocal cords, and parts of the esophagus ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
(Date:9/22/2014)... Sept. 22, 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that its Board of Directors ... conditional proposal from Endo International plc ("Endo") and, ... advisors, has unanimously determined it is not a ... merger agreement with QLT Inc. ("QLT") and has ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... DecisionView Inc., a leading provider of ... life sciences companies, today announced the release of ... flagship solution for patient enrollment planning, tracking and ... into site performance and cost projections, StudyOptimizer 4.3 ...
... 19, 2011 Reportlinker.com announces that ... available in its catalogue: ... http://www.reportlinker.com/p0358494/North-American-External-Defibrillator-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices ... state of the North American external ...
Cached Medicine Technology:DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 2DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 3North American External Defibrillator Market 2North American External Defibrillator Market 3North American External Defibrillator Market 4North American External Defibrillator Market 5North American External Defibrillator Market 6
(Date:9/22/2014)... percent of patients undergoing breast cancer surgery require additional ... cancerous tissue in the initial operation. However, researchers at ... tool they developed that will help surgeons better distinguish ... chances for repeat operations. , The ... 2014 in the Proceedings of the National Academy ...
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... York, New York (PRWEB) September 22, 2014 ... associated with the use of power morcellators ( ... LLP notes a new report detailing the continued ... warnings from federal regulators that specifically discouraged these ... physicians believe that the potential cancer risks associated ...
(Date:9/22/2014)... CareFlight Air & Mobile Services of Miami ... N3+ Dauphin, the latest version of Airbus Helicopters outstanding ... at Miami Valley Hospital in Dayton, Ohio, ... helicopters. , “We have a lot of confidence in ... Emergency, Trauma, and CareFlight. “We’ve been operating Dauphins for ...
Breaking Medicine News(10 mins):Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... Discoveries are exciting but roadblocks remain, experts say , , ... future, people may routinely have doctors scan their personal ... help prevent, spot or treat a cancer. , "We ... a revolution in cancer care," said Dr. Len Lichtenfeld, ...
... With the Help of Leading Medical and Lifestyle Experts ... - the National Psoriasis Foundation is Empowering ... Expanded Web Resources, NEW YORK, Sept. 15 ... have a new resource. Today,the National Psoriasis Foundation officially ...
... disorder is widespread but can be prevented , FRIDAY, Sept. ... the diagnosis, management and prevention of a widespread, deadly lung ... 15 percent to 25 percent of adults over the age ... in the United States. It,s expected to become the fifth ...
... way to motivate the billion people in the world ... an overwhelming task, but a University of Houston professor ... his own. , Ioannis Pavlidis, a UH computer science ... have developed a computer game that translates physical activity ...
... Mozambique, Sept. 14 Aid provided by,The Prem Rawat ... 300 women and their families who were victims of ... After the flooding, caused by cyclones in this ... were displaced from their homes. The,Prem Rawat Foundation made ...
... 14 MAKO Surgical Corp., a,developer of minimally ... today that Frederic H. Moll, M.D.,has been named ... 24,2007. Dr. Moll has over 20 years ... co-founded Hansen Medical Inc. in September 2002 and,currently ...
Cached Medicine News:Health News:Genetics Hold Promise, Challenges for Cancer Care 2Health News:Genetics Hold Promise, Challenges for Cancer Care 3Health News:Genetics Hold Promise, Challenges for Cancer Care 4Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 3Health News:Experts Publish New Lung Disease Guidelines 2Health News:Weight loss game looking for 'NEAT-o' results 2Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors 2
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... platform with integrated neck. Piston assembly ... an internal spring to recoil back ... Block fits into precision milled cavity ... sized 6.25 - 9.0mm. Designed for ...
Medicine Products: